Literature DB >> 19655094

Biology of glioma cancer stem cells.

Deric M Park1, Jeremy N Rich.   

Abstract

Gliomas, much like other cancers, are composed of a heterogeneous mix of neoplastic and non-neoplastic cells that include both native and recruited cells. There is extensive diversity among the tumor cells, with differing capacity for in vitro and in vivo growth, a property intimately linked to the cell's differentiation status. Those cells that are undifferentiated, self-renewing, with the capacity for developing tumors (tumorigenic) cells are designated by some as cancer stem cells, because of the stem-like properties. These cells may be a critical therapeutic target. However the exact identity and cell(s) of origin of the so-called glioma cancer stem cell remain elusive. Here we review the current understanding of glioma cancer stem cell biology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19655094     DOI: 10.1007/s10059-009-0111-2

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  64 in total

1.  Cortical dysplasia: a possible substrate for brain tumors.

Authors:  Shiyong Liu; Chunqing Zhang; Haifeng Shu; Didier Wion; Hui Yang
Journal:  Future Oncol       Date:  2012-03       Impact factor: 3.404

2.  Cytotoxic effects of two organotin compounds and their mode of inflicting cell death on four mammalian cancer cells.

Authors:  Armando Varela-Ramirez; Margaret Costanzo; Yazmin P Carrasco; Keith H Pannell; Renato J Aguilera
Journal:  Cell Biol Toxicol       Date:  2010-10-31       Impact factor: 6.691

Review 3.  Translational potential of astrocytes in brain disorders.

Authors:  Alexei Verkhratsky; Luca Steardo; Vladimir Parpura; Vedrana Montana
Journal:  Prog Neurobiol       Date:  2015-09-16       Impact factor: 11.685

4.  The LIM-only transcription factor LMO2 determines tumorigenic and angiogenic traits in glioma stem cells.

Authors:  S-H Kim; E-J Kim; M Hitomi; S-Y Oh; X Jin; H-M Jeon; S Beck; X Jin; J-K Kim; C G Park; S-Y Chang; J Yin; T Kim; Y-J Jeon; J Song; Y C Lim; J D Lathia; I Nakano; H Kim
Journal:  Cell Death Differ       Date:  2015-02-27       Impact factor: 15.828

5.  A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.

Authors:  Fabian Wolpert; Isabel Tritschler; Alexander Steinle; Michael Weller; Günter Eisele
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

Review 6.  CD133-targeted niche-dependent therapy in cancer: a multipronged approach.

Authors:  Anthony B Mak; Caroline Schnegg; Chiou-Yan Lai; Subrata Ghosh; Moon Hee Yang; Jason Moffat; Mei-Yu Hsu
Journal:  Am J Pathol       Date:  2014-02-28       Impact factor: 4.307

7.  Low Concentration Microenvironments Enhance the Migration of Neonatal Cells of Glial Lineage.

Authors:  Richard A Able; Celestin Ngnabeuye; Cade Beck; Eric C Holland; Maribel Vazquez
Journal:  Cell Mol Bioeng       Date:  2012-06       Impact factor: 2.321

8.  ZFX regulates glioma cell proliferation and survival in vitro and in vivo.

Authors:  Zhichuan Zhu; Kui Li; Dafeng Xu; Yongjie Liu; Hailiang Tang; Qing Xie; Liqian Xie; Jiwei Liu; Hongtao Wang; Ye Gong; Zelan Hu; Jing Zheng
Journal:  J Neurooncol       Date:  2013-01-16       Impact factor: 4.130

9.  Therapeutic targeting of chemoresistant and recurrent glioblastoma stem cells with a proapoptotic variant of oncolytic herpes simplex virus.

Authors:  Nusrat Jahan; Jae M Lee; Khalid Shah; Hiroaki Wakimoto
Journal:  Int J Cancer       Date:  2017-07-19       Impact factor: 7.396

10.  Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis.

Authors:  Francesco Niola; Xudong Zhao; Devendra Singh; Ryan Sullivan; Angelica Castano; Antonio Verrico; Pietro Zoppoli; Dinorah Friedmann-Morvinski; Erik Sulman; Lindy Barrett; Yuan Zhuang; Inder Verma; Robert Benezra; Ken Aldape; Antonio Iavarone; Anna Lasorella
Journal:  J Clin Invest       Date:  2012-12-17       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.